Harmony Biosciences Holdings, Inc. (HRMY)
A+
Pipeline Grade
Financial Position (from SEC Filings)
$589.7M
Cash & Equivalents
$27.8M
Quarterly Burn Rate
$2,133M
Market Cap
Estimated from most recent SEC quarterly filing. View SEC filings
Drug Pipeline (1 Assets)
| Drug | Phase | Indications |
|---|---|---|
|
PITOLISANT HYDROCHLORIDE
WAKIX |
APPROVED | — |
Upcoming Catalysts
| Date | Event | Drug |
|---|---|---|
| 2026-11-01 | Phase3 Readout | — |
| 2027-04-01 | Phase3 Readout | — |
Active Clinical Trials (12)
| NCT # | Title | Phase | Status | Enrollment |
|---|---|---|---|---|
| NCT06014281 | Examining the Effects of Regular Brief Internet-based Meditation Practice on Mental Health and Well Being | OTHER | Active Not Recruiting | 300 |
| NCT06451978 | You, Me and Nature Pilot Study | OTHER | Active Not Recruiting | 48 |
| NCT07520019 | Study Evaluating the Effect of Nutra Harmony "Biotin, Collagen and Keratin Beauty Complex" Dietary Supplement on Hair Th... | OTHER | Active Not Recruiting | 40 |
| NCT07047378 | ACT-Based Training for Parental Burnout and Child Well-being | OTHER | Recruiting | 120 |
| NCT05536011 | WAKIX® (Pitolisant) Pregnancy Registry | OTHER | Recruiting | 1,329 |
| NCT06220084 | The UPbeating GReek Application of DancE in Parkinson's Disease Clinical Trial | OTHER | Active Not Recruiting | 40 |
| NCT05066217 | An Efficacy and Safety Study of Clemizole HCl in Patients With Lennox-Gastaut Syndrome | PHASE3 | Recruiting | 260 |
| NCT07500090 | A Phase 3 Efficacy and Safety Study of HBS-301 in Participants With Idiopathic Hypersomnia (IH) | PHASE3 | Recruiting | 248 |
| NCT07219485 | A Study of Pitolisant in Participants With Prader-Willi Syndrome | PHASE3 | Enrolling By Invitation | 150 |
| NCT04462770 | A Study of EPX-100 (Clemizole Hydrochloride) in Participants With Dravet Syndrome | PHASE3 | Recruiting | 150 |
| NCT06366464 | A Study of Pitolisant in Patients With Prader-Willi Syndrome | PHASE3 | Recruiting | 134 |
| NCT07675135 | A Phase 3 Efficacy and Safety Study of HBS-301 in Participants With Narcolepsy | PHASE3 | Recruiting | 258 |
Source: ClinicalTrials.gov. Trial status last updated by sponsor — may not reflect current state.